Clinical Trial Update: Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial investigating alpha-lipoic acid as adjunctive therapy for schizophrenia with a focus on oxidative stress, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Alpha Lipoic Acid (alpha-lipoic acid)

Snippet

Sponsor: Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara | Conditions: Schizophrenia, Oxidative Stress | Phase 2, Phase 3 | Status: COMPLETED